Drug Type Small molecule drug |
Synonyms HSK42360 |
Target |
Action inhibitors |
Mechanism BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
BRAF V600 mutation-positive brain cancer | Phase 1 | China | 23 Jul 2025 | |
BRAF mutation Solid Tumors | Phase 1 | China | 25 Jun 2024 | |
Brain Cancer | Phase 1 | China | 25 Jun 2024 | |
Brain metastases | Phase 1 | China | 25 Jun 2024 | |
Central Nervous System Neoplasms | Phase 1 | China | 25 Jun 2024 | |
Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 25 Jun 2024 | |
BRAF V600 mutation-positive Neoplasms | Phase 1 | China | 21 Jun 2024 |
Phase 1 | BRAF mutation Solid Tumors BRAF V600 mutations | 17 | ojzgzfsenb(pdobwtsfxe) = increased creatinine and increased ALT cttnqeuxqn (kyvawkwwxp ) View more | Positive | 30 May 2025 |